Feedback / Questions
Jiataile (sacituzumab tirumotecan) - Merck (MSD)
https://www.prnewswire.com/news-releases/third-indication-for-kelun-biotechs-trop2-adc-sac-tmt-approved-for-marketing-by-nmpa-in-egfrm-nsclc-following-progression-on-egfr-tki-therapy-302581297.html
Oct 11, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next